Jonathan Wolleben
Stock Analyst at Citizens
(4.52)
# 220
Out of 5,182 analysts
246
Total ratings
51.03%
Success rate
25.3%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Reiterates: Market Outperform | $132 | $93.44 | +41.27% | 15 | Apr 21, 2026 | |
| DBVT DBV Technologies | Maintains: Market Outperform | $45 → $47 | $20.97 | +124.13% | 17 | Mar 27, 2026 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $29 → $28 | $19.41 | +44.26% | 7 | Mar 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $152 → $155 | $86.59 | +79.01% | 9 | Mar 20, 2026 | |
| SPRB Spruce Biosciences | Maintains: Market Outperform | $180 → $170 | $57.00 | +198.25% | 10 | Mar 10, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $105 → $96 | $38.47 | +149.55% | 19 | Mar 2, 2026 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $120 → $113 | $46.96 | +140.63% | 12 | Feb 27, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $102 → $112 | $99.17 | +12.94% | 14 | Feb 26, 2026 | |
| SION Sionna Therapeutics | Initiates: Market Outperform | $63 | $38.86 | +62.12% | 1 | Feb 24, 2026 | |
| QNCX Quince Therapeutics | Downgrades: Market Perform | n/a | $1.19 | - | 3 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $527 → $745 | $524.00 | +42.18% | 15 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $35 | $8.85 | +295.48% | 9 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $11 → $10 | $5.27 | +89.75% | 10 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $14 | $2.79 | +401.79% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $27 → $25 | $9.01 | +177.47% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $6.00 | +233.33% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $9.60 | +202.24% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $4.37 | +311.90% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $29.19 | +78.14% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.54 | +419.48% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $1.02 | +1,370.59% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.94 | +173.78% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $31.35 | +21.21% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $46.65 | +7.18% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $36.29 | +148.00% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $139.50 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $426.34 | +13.76% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $64 | $8.79 | +628.10% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $28.17 | -14.80% | 1 | May 12, 2023 |
Mirum Pharmaceuticals
Apr 21, 2026
Reiterates: Market Outperform
Price Target: $132
Current: $93.44
Upside: +41.27%
DBV Technologies
Mar 27, 2026
Maintains: Market Outperform
Price Target: $45 → $47
Current: $20.97
Upside: +124.13%
KalVista Pharmaceuticals
Mar 26, 2026
Maintains: Market Outperform
Price Target: $29 → $28
Current: $19.41
Upside: +44.26%
Rhythm Pharmaceuticals
Mar 20, 2026
Maintains: Market Outperform
Price Target: $152 → $155
Current: $86.59
Upside: +79.01%
Spruce Biosciences
Mar 10, 2026
Maintains: Market Outperform
Price Target: $180 → $170
Current: $57.00
Upside: +198.25%
Crinetics Pharmaceuticals
Mar 2, 2026
Maintains: Market Outperform
Price Target: $105 → $96
Current: $38.47
Upside: +149.55%
Structure Therapeutics
Feb 27, 2026
Maintains: Market Outperform
Price Target: $120 → $113
Current: $46.96
Upside: +140.63%
Protagonist Therapeutics
Feb 26, 2026
Maintains: Market Outperform
Price Target: $102 → $112
Current: $99.17
Upside: +12.94%
Sionna Therapeutics
Feb 24, 2026
Initiates: Market Outperform
Price Target: $63
Current: $38.86
Upside: +62.12%
Quince Therapeutics
Jan 30, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $1.19
Upside: -
Jan 20, 2026
Maintains: Market Outperform
Price Target: $527 → $745
Current: $524.00
Upside: +42.18%
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $8.85
Upside: +295.48%
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $5.27
Upside: +89.75%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $2.79
Upside: +401.79%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $9.01
Upside: +177.47%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $6.00
Upside: +233.33%
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $9.60
Upside: +202.24%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $4.37
Upside: +311.90%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $29.19
Upside: +78.14%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $1.54
Upside: +419.48%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.02
Upside: +1,370.59%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.94
Upside: +173.78%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $31.35
Upside: +21.21%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $46.65
Upside: +7.18%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $36.29
Upside: +148.00%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $139.50
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $426.34
Upside: +13.76%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $64
Current: $8.79
Upside: +628.10%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $28.17
Upside: -14.80%